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Founded in 1981, the National Alopecia Areata Foundation (NAAF) is dedicated to
research to find a cure or acceptable treatment for alopecia areata (AA), to
develop support for people affected by the disease, and to educate the public
about it. NAAF has developed into an international organization advancing patient
interests in a number of ways. Beginning in 2008, NAAF organized a series of
research summits that focused AA research investments into genetic, molecular,
and immunological investigations as well as laying the groundwork for clinical
trials and support for regulatory evaluation of prospectively available treatments.
This multifaceted initiative is called the Alopecia Areata Treatment Development
Program (TDP). It is representative of initiatives among voluntary patient advocacy
organizations to partner with academic, clinical, government, and biotechnology
interests to accelerate the development and approval of treatments for under-
studied diseases. The article describes key steps in the development of TDP, its
progress, and future direction.
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The National Alopecia Areata Foun-
dation (NAAF) was founded in 1981 as
a nonprofit organization dedicated to
research to find a cure or acceptable
treatment for alopecia areata (AA), to
support people affected by the disease,
and to educate the public about it.
NAAF has developed into an interna-
tional organization advancing patient
interests and providing information and
services through local support groups,
via print and digital communications
resources, and an annual patient–
family conference. From its beginnings,
NAAF partnered with leading dermato-
logy researchers and practitioners to
increase knowledge about the disease
and to generate best practices for care.
NAAF engages in advocacy to reach
out to policy makers and government
agencies such as National Institute of
Health and the Food and Drug Admin-
istration and to educate them about
AA and the importance of advancing
the search for treatments and effective
care.
After nearly three decades of funding
research, including grants for postdoc-
toral fellowships and investigator-initi-
ated studies, NAAF invited AA–focused
scientists, health-care practitioners, and
representatives of government agencies
to a research summit in June 2008.
The summit’s purpose was to review
the status of AA knowledge and to deve-
lop a strategic plan for achieving effec-
tive and safe treatments. The summit
focused on growing genetic and immuno-
logical research and concluded that
coordinated initiatives in these areas offer
great promise to achieve breakthroughs
in understanding disease pathophysiology
and for finding approvable treatments.
At its conclusion, meeting participants
also recommended using the National
Alopecia Areata Registry for research,
using available animal models, and
repurposing existing medications.
The next year, NAAF organized a
second research summit inviting leading
immunologists, geneticists, and derma-
tologists from around the world to iden-
tify joint or complementary approaches
to AA research. The summit concluded
with a focused strategy for accelerating
immunological and genetic research
and recognition of the importance of
National Alopecia Areata Registry as a
research resource for both basic and
future clinical investigations. Summit
participants encouraged NAAF to have
a central role in coordinating initiatives,
advocacy, funding, and to act as a
concierge to help encourage fellowships
at leading research centers.
Following the 2009 summit, NAAF
formalized its focus on treatment acce-
leration by announcing the Alopecia
Areata Treatment Development Program
(TDP) and developing a detailed busi-
ness plan to support it. Approved by the
NAAF Board of Directors in 2010, TDP
has made investments in antibody and
antigen studies and has plans through
the end of 2016 for other basic science
initiatives as well as for animal, clinical,
and research supportive of regulatory
evaluation. By then, NAAF hopes to
have achieved greater understanding
of the immune processes causing AA
and to have results from initial clinical
trials focused on new and repurposed
treatments.
A research breakthrough reinforced
the conclusion that TDP was headed
in the right direction. A genome-wide
association study published in Nature
identified several genetic locations
that contribute to disease susceptibility,
generating new pathways to therapy
exploration based on underlying AA
mechanisms, particularly focusing
on mechanisms common to other
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autoimmune diseases (Petukhova et al.,
2010).
Later that year, NAAF sponsored a
third AA research summit focused on
clinical and translational research as
well as complementary studies and
policies needed to support Food and
Drug Administration review of new
treatments such as development of bio-
markers, updated population prevalence
and quality of life studies, and standar-
dized protocols governing AA clinical
trials. These developments were also
translated into updated TDP plans and
budgets.
In late 2011, NAAF began planning a
fourth research summit to be held before
the end of 2012. The effort begun with
the 2008 AA research summit was
achieving the first wave of results from
research initiated in 2010 and 2011 and
there was a need to determine research
priorities for 2013–2016. The 2012
agenda, the longest of the four summits,
shows that AA basic and treatment-
related research is accelerating in all of
the priority areas and has growing pro-
mise to achieve its intended goals.
NAAF’s TDP is representative of a
movement among voluntary patient
advocacy organizations to accelerate
the search for of treatments, particularly
for rare and understudied diseases as
well as for those without tested and
approved treatments. A group of orga-
nizations including NAAF (called The
Research Acceleration and Innovation
Network (TRAIN), 2012) has been
formed by Faster Cures, a nonprofit
organization dedicated to ‘‘accelerating
medical solutions.’’ This movement also
complements the emergence of genetic
and molecular approaches to medical
research and the development of small
biotechnology companies able to secure
resources, often in partnership with
nonprofit patient organizations, to
focus on under-researched diseases.
In 2013, TDP will be in its fourth
year. Through 2012, over $3 million has
been invested in TDP projects with
more investments anticipated in the
program through 2016 (see Figure 1).
The role of the program has also
expanded considerably and includes
an effort to bring patient perspectives
to regulatory processes so that as these
decisions are made the full range of
patient concerns are addressed. NAAF’s
Scientific Advisory Committee has also
been organized into multiple commit-
tees and task groups to focus expert
involvement and decision making. In
addition to patient and family support
and public and patient education, TDP
has become a central focus of NAAF
and its constituency as well as a unify-
ing force among an expanding number
for stakeholders.
Looking ahead, NAAF will build on
the interests of its patient constituency to
accelerate treatment development. It
will continue to encourage their invol-
vement in the Alopecia Areata Clinical
Trials Registry while also partnering
with contributors and academic, com-
mercial, and government partners.
CONFLICT OF INTEREST
The author states no conflict of interest.
ACKNOWLEDGMENTS
Funding for the Summit and publication of this
article was provided by the National Alopecia
Areata Foundation.
REFERENCES
Petukhova L, Duvic M, Hordinsky M et al. (2010)
Genome-wide association study in alopecia
areata implicates both innate and adaptive
immunity. Nature 466:113–8
The Research Acceleration and Innovation
Network (2012) FasterCures [online]. Avail-
able at: http://www.fastercures.org/TRAIN/,
(accessed 26 November 2012)
$3,500,000
TDP: NAAF & external investments
TDP spending/year: NAAF + non-NAAF 2010–2016
(Future non-NAAF investments not included)
$3,000,000
$2,500,000
$2,000,000
$1,500,000
$1,000,000
$500,000
$0
2010 2011 2012 2013 2014
NAAF total Concierge total
2015 2016
Figure 1. National Alopecia Areata Foundation (NAAF) and non-NAAF investments in Alopecia
Areata Treatment Development Program (TDP)–related research through 2012 and prospectively
through 2016 based on NAAF budget plans and known commitments.
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